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Abstract. The degree of hypothalamic-pituitary-adrenal (HPA) axis dysregula- 
tion in depressed patients with schizoaffective disorder was compared to that seen 
in patients with major depressive disorder with and without delusional features. 
The frequency of nonsuppression to dexamethasone was similar for all three 
diagnostic groups. Maximum postdexamethasone plasma cortisol was greater for 
delusional depressives, but did not differ between patients with major depressive 
and schizoaffective disorders. Modest correlations were found between post- 
dexamethasone plasma cortisol levels, severity of illness, age, and recent weight 
loss, for patients with both major depressive disorder and delusional depression. 
For schizoaffective patients, associations between postdexamethasone plasma 
cortisol levels and various measures of severity of illness, but not age and recent 
weight loss, were found. Although HPA axis dysregulation occurs more fre- 
quently in all three of the studied diagnostic groups than in normal individuals, 
factors contributing to this dysregulation may be qualitatively different for 
schizoaffective patients. 
Key Words. Schizoaffective disorder, dexamethasone suppression test, depres- 
sion, hypothalamic-pituitary-adrenal axis dysregulation. 
Many patients with depression have dysregulation of their hypothalamic-pituitary- 
adrenal (HPA) axes. Early investigation suggested that this dysregulation, as 
reflected by nonsuppression of plasma cortisol following oral dexamethasone, might 
be a neuroendocrine correlate of endogenous depression (Carroll et al., 1981). 
Subsequently, it has become apparent that some nonendogenously depressed 
patients also have evidence of HPA axis dysregulation, although fewer of these 
patients have abnormal dexamethasone suppression test (DST) results (Mendlewicz 
et al., 1982; Brown et al., 1985). Thus, it seems that this dysregulation may reflect the 
severity of affective disturbance and is not specific for any particular subtype of 
depression. 
A role of psychosis in HPA axis dysregulation also has been proposed. Patients 
with delusional depression have abnormal DST results, often demonstrating higher 
postdexamethasone plasma cortisol levels than depressed patients without psychosis 
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(Mendlewicz et al., 1982; Rothschild et al., 1982; Rudorfer et al., 1982; Schatzberg et 
al., 1983). The nature of HPA axis functioning in schizoaffective disorder is less 
clear; while some investigators have found high degrees of HPA disturbances in 
schizoaffective patients (Carman et al., 1981; Aguilar et al., 1984; Sauer et al., 1984), 
others have found considerably less abnormality (Greden et al., 1981; Coccaro et al., 
1985; Katona and Roth, 1985). The present study was designed to explore the nature 
of HPA axis functioning in patients with schizoaffective disorder by examining both 
continuous and dichotomous postdexamethasone plasma cortisol responses in a 
large sample while simultaneously considering potential sources of variance known 
to contribute to HPA axis dysregulation. 
Methods 
Subjects were 84 inpatients at the Clinical Studies Unit, a 12-bed research component of the 
University of Michigan Depression Program. All patients were hospitalized on the unit during 
the period from 1977 to 1985. Diagnoses were made by consensus Research Diagnostic 
Criteria (RDC) (Spitzer et al., 1977) following a comprehensive diagnostic evaluation 
involving several unstructured clinical interviews by psychiatrists, and a structured interview 
by a trained research staff member using the Schedule for Affective Disorders and 
Schizophrenia (Spitzer and Endicott, 1975). For the present study, 49 patients had major 
depressive disorder (MDD), IO MDD with psychotic features, and 25 schizoaffective disorder, 
depressed subtype. 
After at least a 2-week medication washout period, each patient underwent a I mg DST 
(Carroll et al., 1981), with plasma samples obtained for cortisol determination at 8 a.m., 4 
p.m., and I I p.m. on the following day. Cortisol was determined by a modification of 
Murphy’s (1967) competitive protein-binding technique. Intra-assay and interassay 
coefficients of variation in our laboratory are 5% and 7%, respectively. Patients with 
identifiable technical exclusions known to invalidate the DST (Carroll et al., 1981) were not 
studied. For all patients, the 17-item Hamilton Rating Scale for Depression (HRSD) 
(Hamilton, 1960), and for only the schizoaffective patients, the Global Assessment Scale 
(GAS) and the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962), were 
administered at the same time that the DST was performed. 
HPA axis function was compared between diagnostic groups by two methods. Patients 
were categorized as DST suppressors or nonsuppressors (Carroll et al., 1981), using a 
maximum postdexamethasone plasma cortisol level of > 5 pg/dl as a referent value (@eden, 
1985), a level that has been validated in our facility. Between-group comparisons were by x2 
analysis. In addition, absolute levels of postdexamethasone plasma cortisol levels were 
logarithmically transformed because the values were not normally distributed, and compared 
between groups by one-way analysis of variance (ANOVA). The relationships between the 
clinically relevant variables, severity of illness, age, and degree of recent weight change, and 
logarithmically transformed maximum postdexamethasone plasma cortisol levels were 
estimated using Pearson’s product-moment correlation coefficients. All reported means are 
f standard deviations. 
Results 
Clinical and demographic variables for the three subgroups are shown in Table 1, 
and were compared between diagnostic groups by one-way ANOVA. None of the 
between-diagnosis differences were significant, except for age (F= 7.64, p < 0.001); 
the depressed schizoaffective patients were significantly younger than patients with 
major depressive disorder with and without delusional features. 
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Table 1. Demographic and clinical characteristics of study patients 
Variable 
Past depressive episodes 
Age at first depressive episode 
Past depressive hospitalizations 
Past suicide attempts 
Sex (male/female) 
Age 
Weight loss (kg) 
HRSD score 
MDD 
(n = 49) 
2.6 + 2.9 
34.4 f 15.2 
1.8 f 2.1 
0.8 zt 1.8 
16133 
46.2 f 16.3’ 
1.47 f 8.26 
21.1 f 5.8 
MDP 
(n = 10) 
4.0 f 3.5 
39.5 f 17.4 
2.4 f 2.6 
0.6 + 0.7 
416 
53.0 f 17.42 
2.86 f 3.53 
22.8 f 10.7 
SZD 
(n = 25) 
2.0 f 2.9 
26.2 f 13.0 
1.7 zt 2.3 
1.1 + 1.3 
9116 
33.4 f 10.5 
2.60 f 8.34 
21.2 f 7.9 
Note. Data are presented as mean f SD. MDD = major depressive disorder. MDP = MDD with delusional features. 
SZD = schizoaffective disorder, depressed. HRSD = Hamilton Rating Scale for Depression. 
1. MDD vs. SZD. p < 0.001. 
2. MDP vs. SZD, p < 0.005. 
Postdexamethasone plasma cortisol responses are shown in Fig. 1 and are 
summarized in Table 2. Delusional depressives had significantly higher plasma 
cortisol levels than both depressed schizoaffective patients (F= 4.83, p < 0.02) and 
patients with major depressive disorder (F= 4.47, p < 0.02). As significant between- 
group age differences were found, this analysis was also performed by analysis of 
covariance (ANCOVA). When age was introduced as a covariate, this difference 
persisted for patients with major depressive disorder (F = 3.43, p < 0.05), but not 
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MDD = major depressive disorder. MDP = MDD with delusional features. SZD = schizoaffective disorder, 
depressed subtype. 
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schizoaffective disorder (depressed subtype). The percentage of DST nonsuppressors 
for each of the three diagnostic groups was not significantly different (Table 2). 
Table 2. Postdexamethasone cortisol responses in study patients 
Variable MDD MDP SZD 
Frequency of DST nonsuppression 20/49 (41%) 6/i 0 (60%) 8125 (32%) 
Maximum postdexamethasone cortisol 6.02 f 6.002 10.58 ?C 5.50* 5.48 + 4.902 
Age-adjusted maximum cortisoIi 5.73 z!= 5.60 9.68 -f 6.323 6.39 f 6.10 
Note. Results are presented as mean f SO. MOD = major depressive disorder. MDP = MDD with delusional features. 
SZD = schizoaffective disorder, depressed. DST = dexamethasone suppression test. 
1. Results of analysis of covariance, with age as covariate. 
2. MDP vs. MDD and MDP vs. SZD, p < 0.02. 
3. MDP vs. MDD, p < 0.05. 
In a further attempt to characterize the response of schizoaffective patients to the 
DST, this group was reexamined following segregation into RDC “mainly 
schizophrenic” and “mainly affective” subgroups; this information, however, was 
only available for 15 of the 25 patients. The number of DST nonsuppressors in each 
subgroup was not significantly different (I / 5 mainly schizophrenic and 5/ 10 mainly 
affective schizoaffective patients; x 2 = 1.25, p = NS). Mean (+ SD) postdexa- 
methasone plasma cortisol levels were also not significantly different between these 
two subgroups (4.1 + 3.9 and 5.7 f 4.9 for mainly schizophrenic and affective 
subgroups, respectively; F = 0.4 I, p = NS). There were no differences between the 
two subgroups for any of the clinical and demographic variables listed in Table I 
except for age; the mainly schizophrenic schizoaffective patients tended to be 
somewhat younger than the mainly affective subgroup (25.0 k 4.8 vs. 36.1 + 8.7 
years), although this difference did not change interpretation of the cortisol data 
when ANCOVA was subsequently employed. 
Table 3 summarizes the associations between clinically relevant variables (severity 
Table 3. Coefficients of correlation between clinically relevant 




















Note. MDD = major depressive disorder. MDP = MDD with deluslonal features. SZD = schizo- 
affective disorder, depressed. HRSD = Hamilton Rating Scale for Depression. GAS = Global 
Assessment Scale. BPRS = Brief Psychiatric Rating Scale. 
1. p < 0.05. 
2. p < 0.01. 
3. Due to nature of the GAS scale (increasing value implying better functioning and lower 
symptomatology, the reverse of the HRSD and BPRS scales), an association between severity and 
postdexamethasone plasma cortisol would be expected to be Inversely related, hence the negative 
r value. 
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of illness, age, and degree of recent weight change) and cortisol values. Moderate to 
high degrees of correlation were found between postdexamethasone plasma cortisol 
levels and measures of severity of illness (HRSD, BPRS, and GAS scores) for all 
three disorders. Moderate associations were found between age and degree of recent 
weight loss for major depressive disorder with and without delusional features, but 
not for schizoaffective disorder (depressed subtype). 
Discussion 
Previous studies on postdexamethasone cortisol responses in patients with schizo- 
affective disorder have focused on the dichotomous DST suppressor/nonsuppressor 
status, and the results have been variable. Many investigators have reported a fairly 
low rate of nonsuppression in schizoaffective disorder. Coccaro et al. (1985) found 
that only two of nine schizoaffective patients were nonsuppressors, compared with 
90% of patients with psychotic depression. As these authors noted, however, the 
schizoaffective patients included in their study were a mainly schizophrenic rather 
than affective subgroup. In a previous study from our group (Greden et al., 1981) 
using a largely different, earlier cohort of patients, 24% of schizoaffective depressed 
patients were found to be DST nonsuppressors-a rate of nonsuppression between 
those of patients with schizophrenia and endogenous depression. Katona and Roth 
(1985) reported a similar nonsuppression rate of 30% in their study of 30 schizo- 
affective patients, although Katona and Roth’s patients were not medication-free, 
which may confound interpretation of their results. 
Other investigators have reported much higher rates of DST nonsuppression. 
Carman et al. (1981) indicated that 51% of the schizoaffective patients in their study 
were nonsuppressors, although they did not indicate their total sample size. In a 
study examining the diagnostic specificity of the DST, Aguilar et al. (1984) found 
that 9 of 13 schizoaffective patients were DST nonsuppressors, yielding a 
nonsuppression rate of 69%. The largest DST nonsuppression rate in depressed 
schizoaffective patients reported to date was 89% of a study group of I8 patients 
(Sauer et al., 1984). Thus, the range of reported DST nonsuppression rates in 
depressed schizoaffective patients is from 20% to 89%, indicating substantial 
disagreement among reports. This wide range of values may reflect the considerable 
heterogeneity of patients classified as schizoaffective in current nosological systems. 
It is now well established that various cortisol assays may differ considerably from 
each other. This ensures that there will be relatively high variance in “suppression” 
and “nonsuppression” rates if the referent value of 5 pug/d1 has been established in 
one setting (Carroll et al., 198 I), but a different assay is used in other settings. Thus, 
a more accurate reflection of HPA regulation may be provided by examining 
absolute values of cortisol. Results of this type of analysis have also been variable in 
the study of depressed schizoaffective patients. Coccaro et al. (1985) found that 
patients with psychotic depression had significantly higher postdexamethasone 
plasma cortisol levels than patients with schizoaffective disorder, at both 4 p.m. and 
I I p.m. Two studies have compared postdexamethasone plasma cortisol levels 
between depressed schizoaffective and endogenous depressive patients. In one 
(Greden et al., 1981), endogenous depressive patients had postdexamethasone 
plasma cortisol values twice those found in schizoaffective patients, whereas the 
second (Sauer et al., 1984) found that schizoaffective patients had higher cortisol 
levels than endogenous depressive patients. Neither of these studies, however, 
corrected for the possible effect of age. We found that patients with psychotic 
depression had significantly higher postdexamethasone plasma cortisol levels than 
patients with major depressive disorder and a trend to this difference persisted when 
results were corrected for age, a finding in agreement with many previous reports 
(Mendlewicz et al., 1982; Rothschild et al., 1982; Rudorfer et al., 1982; Schatzberg et 
al., 1983). Psychotic depressive patients also had higher cortisol levels than depressed 
schizoaffective patients, similar to the report of Coccaro et al. (1985); this difference 
did not persist, however, when age was introduced as a covariate. We found no 
difference between postdexamethasone plasma cortisol levels in schizoaffective 
disorder and major depressive disorder; unlike previous studies (Greden et al., 1981; 
Sauer et al., 1984) we did not restrict the group of patients with major depressive 
disorder to only those patients with endogenous depression. 
It is apparent from these data and those from previous studies that a significant 
percentage of patients with schizoaffective disorder manifest some degree of HPA 
axis dysregulation as reflected by postdexamethasone plasma cortisol levels, but to a 
considerably lesser extent than that found in delusional depression. Rather, 
schizoaffective patients appear to have postdexamethasone plasma cortisol levels 
more like those of patients with major depressive disorder without psychotic 
features. Thus, although patients with delusional depression have the highest 
postdexamethasone plasma cortisol levels, the presence of psychosis in and of itself is 
not sufficient to account for this difference; this conclusion is further supported by 
previous work by Rothschild et al. (1982) who showed that psychotic schizophrenic 
patients did not have elevated postdexamethasone plasma cortisol levels. 
Certain clinical and demographic variables have been shown to be related to the 
degree of HPA axis dysregulation seen in affective disorders. Age (Oxenkrug et al., 
1983; Davis et al., 1984; Lewis et al., 1984), severity of illness (Krishnan et al., 1985~; 
Kumar et al., 1986; Meador-Woodruff et al., 1987), and degree of recent weight 
change (Keitner et al., 1985; Krishnan et al., 19856) appear to be three of the most 
important determinants of HPA axis dysregulation observed in depression. All three 
of these factors were found to be partial determinants of HPA axis dysregulation in 
major depressive disorder, with or without psychotic features-similar to findings in 
previous reports. A different pattern, however, was observed for the depressed 
schizoaffective patients. Severity of depression and psychosis ratings were correlated 
with postdexamethasone plasma cortisol levels; a modest association was observed 
for the depression severity ratings; and a much more significant relationship was seen 
for the psychosis factors. Age and weight loss, on the other hand, showed no 
association with plasma cortisol values. These findings suggest that although the 
mean postdexamethasone plasma levels might be similar in patients with major 
depressive and schizoaffective disorders, the factors contributing to the observed 
HPA axis dysregulation in these two groups may be different, perhaps reflecting 
differences in underlying neurotransmitter substrates. Stated differently, the 
underlying pathophysiology may explain both differences in clinical features and 
neuroendocrine findings. Additionally, severity of illness may generally be a key 
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determinant of HPA axis dysregulation in various affective disorders, as it was 
found to be correlated with postdexamethasone cortisol levels in all three disorders 
studied. 
The HPA axis abnormalities observed in patients with psychiatric disorders are 
beginning to be more fully understood. It is now accepted that they are not restricted 
to patients with endogenous depression. Instead, HPA axis abnormalities exist in 
many patients with various subtypes of affective disorders, both with and without 
psychotic features. Whether this HPA axis abnormality is a marker specific for 
affective disorders or, rather, a reflection of underlying limbic dysregulation, 
modified by age, weight loss, severity of symptoms, and the presence or absence of 
psychosis, remains to be determined. 
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